LOGIN TO YOUR ACCOUNT

Username
Password
Remember Me
Or use your Academic/Social account:

CREATE AN ACCOUNT

Or use your Academic/Social account:

Congratulations!

You have just completed your registration at OpenAire.

Before you can login to the site, you will need to activate your account. An e-mail will be sent to you with the proper instructions.

Important!

Please note that this site is currently undergoing Beta testing.
Any new content you create is not guaranteed to be present to the final version of the site upon release.

Thank you for your patience,
OpenAire Dev Team.

Close This Message

CREATE AN ACCOUNT

Name:
Username:
Password:
Verify Password:
E-mail:
Verify E-mail:
*All Fields Are Required.
Please Verify You Are Human:
fbtwitterlinkedinvimeoflicker grey 14rssslideshare1
PATEL, NEIL (2016)
Languages: English
Types: Doctoral thesis
Subjects: R1
COPD is a debilitating chronic respiratory disease with a systemic footprint. COPD is a highly heterogeneous disease but invariably its management involves a one-size fits all approach. This fails to address individual variations in disease progression, symptom burden and functional decline. There remains a need for sensitive monitoring tools that could provide personalised care based on patients’ particular phenotypes and informative self-management. \ud \ud This thesis has standardised collection protocols and processing for saliva, a complex bodyfluid\ud which is readily accessible and user-friendly for near-patient testing. I have modified immunoassays to work in saliva with demonstrable reproducible results for quantification of C-reactive protein, Procalcitonin and Neutrophil Elastase. Symptom assessment is crucial in\ud longitudinal self-monitoring of COPD. I designed a novel patient wellbeing scale incorporated into an electronic self-assessment diary, which was embraced by patients as improving symptom change recognition, education and self-management. Using sophisticated analytical tools, I have attempted to cluster/phenotype disease trajectory paths driven by a compilation of symptom scores, spirometric volumes and saliva biomarker levels and produced novel patientspecific multidimensional composite scores with significant correlation to COPD disease severity. Prodromal changes in FEV1, salivary biomarkers and self-assessment scores were reproducibly demonstrated, with potential to predict exacerbation onset.\ud \ud These results could be exploited for the development of a much-needed personalised COPD monitoring eco-system, which isolates early deteriorations and prompts timely interventions, leading to beneficial disease outcomes. Patient-researcher iterative co-design has been key\ud throughout this thesis. One outcome of this relationship is the design and production of a bespoke integral saliva collector prototype which could substitute laboratory-based processing of saliva samples in readiness for analyte testing.\ud \ud In conclusion, this thesis has created the necessary tools to improve the classification and monitoring of COPD, opening new avenues for proactive patient self-management and providing the basis for future personalised and stratified care.
  • The results below are discovered through our pilot algorithms. Let us know how we are doing!

    • 1.6.2. Aetiology of an exacerbation
    • 1.6.3. Burden of an exacerbation
    • 1.7. Development of COPD monitoring tools
    • 1.7.1. Novel monitoring approaches in COPD
    • 1.7.1.1. Electronic nose breath analysis
    • 1.7.1.2. Exhaled breath condensate
    • 1.7.1.3. Urine
    • 1.7.1.4. Dried blood spot
    • 1.8. Saliva
    • 1.8.1. Gland specific or whole saliva sampling
    • 1.8.2. Differences between stimulated and unstimulated saliva 1.8.3. Technological approaches to salivary analysis
    • 1.8.3.1. Mass spectrometry
    • 1.8.3.2. Lateral flow assays
    • 1.8.3.3. Microfluidic technology: Lab-on-a-chip
    • 1.8.3.3.1. Microspheres
    • 1.8.3.4. Immunoassays
    • 1.8.3.4.1. Immunoassay labels
    • 1.8.3.4.1.1. Enzyme
    • 1.8.3.4.1.2. Radioactive isotope
    • 1.8.3.4.1.3. Fluorophore
    • 1.8.3.4.1.4. Chemiluminescence
    • 1.8.3.4.1.5. Liposome
    • 1.9. Salivary analysis in COPD
    • 1.9.1. C-Reactive Protein (CRP) patients does not reflect cytokine-induced protein profiles of neutrophils in vitro. BMC Pulm Med, 11, 44.
    • LANGSETMO, L., PLATT, R. W., ERNST, P. & BOURBEAU, J. 2008. Underreporting exacerbation of chronic obstructive pulmonary disease in a longitudinal cohort. Am J Respir Crit Care Med, 177, 396-401.
    • LAURITSEN, K., INNOCENTI, A. D., HENDEL, L., PRAEST, J., LYTJE, M. F., CLEMMENSEN-ROTNE, K. & WIKLUND, I. 2004. Symptom recording in a randomised clinical trial: paper diaries vs. electronic or telephone data capture. Control Clin Trials, 25, 585-597.
    • LEE, V. M. & LINDEN, R. W. A. 1991. An olfactory parotid-salivary reflex in humans? Exp Physiol, 76, 347-355.
    • LEE, V. M. & LINDEN, R. W. A. 1992. An olfactory-submandibular salivary reflex in humans. Exp Physiol, 77, 221-224.
    • LEHMANN, C., WILKENING, A., LEIBER, D., MARKUS, A., KRUG, N., PABST, R. & TSCHERNIG, T. 2001. Lymphocytes in the bronchoalveolar space reenter the lung tissue by means of the alveolar epithelium, migrate to regional lymph nodes, and subsequently rejoin the systemic immune system. Anat Rec, 264, 229-236.
    • LEHMANN, S., DELABY, C., VIALARET, J., DUCOS, J. & HIRTZ, C. 2013. Current and future use of “dried blood spot” analyses in clinical chemistry. Clin Chem Lab Med, 51, 1897-1909.
    • LEIDY, N. K., SEXTON, C. C., JONES, P. W., NOTTE, S. M., MONZ, B. U., NELSEN, L., GOLDMAN, M., MURRAY, L. T. & SETHI, S. 2014. Measuring respiratory symptoms in clinical trials of COPD: reliability and validity of a daily diary. Thorax, 69, 443-449.
    • LEUPPI, J. D., SCHUETZ, P., BINGISSER, R. & ET AL. 2013. Short-term vs conventional glucocorticoid therapy in acute exacerbations of chronic obstructive pulmonary disease: the reduce randomized clinical trial. JAMA, 309, 2223-2231.
    • LI, C. F., HA, T. Z., FERGUSON, D. A., CHI, D. S., ZHAO, R. G., PATEL, N. R., KRISHNASWAMY, G. & THOMAS, E. 1996. A newly developed PCR assay of Hpylori in gastric biopsy, saliva, and feces - evidence of high prevalence of H-pylori in saliva supports oral transmission. Dig Dis Sci, 41, 2142-2149.
    • LI, C., FRIEDMAN, B., CONWELL, Y. & FISCELLA, K. 2007. Validity of the Patient Health Questionnaire 2 (PHQ-2) in identifying major depression in older people. J Am Geriatr Soc, 55, 596-602.
    • LI, X. Y., GILMOUR, P. S., DONALDSON, K. & MACNEE, W. 1996. Free radical activity and pro-inflammatory effects of particulate air pollution (PM10) in vivo and in vitro. Thorax, 51, 1216-1222.
    • LI, Z., WANG, Y., WANG, J., TANG, Z., POUNDS, J. G. & LIN, Y. 2010. Rapid and sensitive detection of protein biomarker using a portable fluorescence biosensor based on quantum dots and a lateral flow test strip. Anal Chem, 82, 7008-7014.
    • LIMA, D. P., DINIZ, D. G., MOIMAZ, S. A., SUMIDA, D. H. & OKAMOTO, A. C. 2010. Saliva: reflection of the body. Int J Infect Dis, 14, e184-188.
    • LING, S. H. & VAN EEDEN, S. F. 2009. Particulate matter air pollution exposure: role in the development and exacerbation of chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis, 4, 233-243.
    • LIPPS, B. V. 2008. Part 3: elevated levels of the salivary protein immunoglobulon E, nerve growth factor, myoglobin and insulin in patients with type 2 diabetes or with autoimmunity can be prevented with LT-10 treatment. Toxin Rev, 27, 109-123.
    • LITSTER, A. L., PRESSLER, B., VOLPE, A. & DUBOVI, E. 2012. Accuracy of a point-ofcare ELISA test kit for predicting the presence of protective canine parvovirus and canine distemper virus antibody concentrations in dogs. Vet J, 193, 363-366.
    • LIU, D., PENG, S. H., ZHANG, J., BAI, S. H., LIU, H. X. & QU, J. M. 2015. Prediction of short term re-exacerbation in patients with acute exacerbation of chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis, 10, 1265-1273.
    • LIU, S. F., LIN, K. C., CHIN, C. H., CHEN, Y. C., CHANG, H. W., WANG, C. C. & LIN, M. C. 2007. Factors influencing short-term re-admission and one-year mortality in patients with chronic obstructive pulmonary disease. Respirology, 12, 560-565.
    • LOCKHART, W., SMITH, D. H., MAIR, A. & WILSON, W. A. 1960. Practical experience with the peak flow meter. Br Med J, 1, 37-38.
    • LOESCHE, W. J., BROMBERG, J., TERPENNING, M. S., BRETZ, W. A., DOMINGUEZ, B. L., GROSSMAN, N. S. & LANGMORE, S. E. 1995. Xerostomia, xerogeneic medications and food avoidance in selected geriatric groups. J Am Geriatr Soc, 43, 401- 407.
    • LOO, J. A., YAN, W., RAMACHANDRAN, P. & WONG, D. T. 2010. Comparative human salivary and plasma proteomes. J Dent Res, 89, 1016-1023.
    • LOPEZ-CAMPOS, J. L., RUIZ-RAMOS, M. & SORIANO, J. B. 2014. Mortality trends in chronic obstructive pulmonary disease in Europe, 1994-2010: a joinpoint regression analysis. Lancet Respir Med, 2, 54-62.
    • LOUBIERE, S. & MOATTI, J. P. 2010. Economic evaluation of point-of-care diagnostic technologies for infectious diseases. Clin Microbiol Infect, 16, 1070-1076.
    • LUCAS, S. D., COSTA, E., GUEDES, R. C. & MOREIRA, R. 2013. Targeting COPD: advances on low-molecular-weight inhibitors of human neutrophil elastase. Med Res Rev, 33, E73-101.
    • LUCEY, E. C., GOLDSTEIN, R. H., STONE, P. J. & SNIDER, G. L. 1998. Remodeling of alveolar walls after elastase treatment of hamsters. Results of elastin and collagen mRNA in situ hybridisation. Am J Respir Crit Care Med, 158, 555-564.
    • LUDVIGSSON, J. F., INGHAMMAR, M., EKBERG, M. & EGESTEN, A. 2011. A nationwide cohort study of the risk of chronic obstructive pulmonary disease in coeliac disease. J Intern Med, 271, 481-489.
    • LUISETTI, M., MA, S., IADAROLA, P., STONE, P. J., VIGLIO, S., CASADO, B., LIN, Y. Y., SNIDER, G. L. & TURINO, G. M. 2008. Desmosine as a biomarker of elastin degradation in COPD: current status and future directions. Eur Respir J, 32, 1146-1157.
    • MA, S., LIN, Y. Y. & TURINO, G. M. 2007. Measurements of desmosine and isodesmosine by mass spectrometry in COPD. Chest, 131, 1363-1371.
    • MA, X. Q., CUI, J. C., WANG, J., CHANG, Y., FANG, Q. H., BAI, C. Q., ZHOU, X. M., ZHOU, H., FENG, H. S., WANG, Y., ZHAO, W. G., WEN, Z. G., WANG, P., LIU, Y., YU, L., LI, C. S. & CHEN, L. A. 2015. Multicentre investigation of pathogenic bacteria and antibiotic resistance genes in Chinese patients with acute exacerbation of chronic obstructive pulmonary disease. J Int Med Res, 43, 699-710.
    • MACKAY, A. J., DONALDSON, G. C., PATEL, A. R. C., SINGH, R., KOWLESSAR, B. & WEDZICHA, J. A. 2014. Detection and severity grading of COPD exacerbations using the exacerbations of chronic pulmonary disease tool (EXACT). Eur Respir J, 43, 735- 744.
    • MACNEE, W. 2001. Oxidative stress and lung inflammation in airways disease. Eur J Pharmacol, 429, 195-207.
    • MACNEE, W. 2005. Pathogenesis of chronic obstructive pulmonary disease. Proc Am Thorac Soc, 2, 258-266.
    • MAJO, J., GHEZZO, H. & COSIO, M. G. 2001. Lymphocyte population and apoptosis in the lungs of smokers and their relation to emphysema. Eur Respir J, 17, 946-953.
    • MALAMUD, D. & RODRIGUEZ-CHAVEZ, I. R. 2011. Saliva as a Diagnostic Fluid. Dent Clin North Am, 55, 159-178.
    • MAN, S. F., CONNETT, J. E., ANTHONISEN, N. R., WISE, R. A., TASHKIN, D. P. & SIN, D. D. 2006. C-reactive protein and mortality in mild to moderate chronic obstructive pulmonary disease. Thorax, 61, 849-853.
    • MANDEL, I. D. 1993. Salivary diagnosis: more than a lick and a promise. J Am Dent Assoc, 124, 85-87.
    • MARIN, A., GARCIA-AYMERICH, J., SAULEDA, J., BELDA, J., MILLARES, L., GARCIA-NUNEZ, M., SERRA, I., BENET, M., AGUSTI, A., ANTO, J. M. & MONSO, E. 2012. Effect of bronchial colonisation on airway and systemic inflammation in stable COPD. COPD, 9, 121-130.
    • MARIN, J. M., ALFAGEME, I., ALMAGRO, P., CASANOVA, C., ESTEBAN, C., SOLERCATALUÑA, J. J., DE TORRES, J. P., MARTÍNEZ-CAMBLOR, P., MIRAVITLLES, M., CELLI, B. R. & SORIANO, J. B. 2013. Multicomponent indices to predict survival in COPD: the COCOMICS study. Eur Respir J, 42, 323-332.
    • MARTIN, J. C. & JETT, J. H. 1986. Apparatus for eliminating background interference in fluorescence measurements. Google Patents.
    • MARUNA, P., NEDELNIKOVA, K. & GURLICH, R. 2000. Physiology and genetics of procalcitonin. Physiol Res, 49, S57-61.
    • MCDADE, T. W., BURHOP, J. & DOHNAL, J. 2004. High-sensitivity enzyme immunoassay for C-reactive protein in dried blood spots. Clin Chem, 50, 652-654.
    • MCLACHLAN, G. & PEEL, D. 2004. Finite mixture models, John Wiley & Sons, 63.
    • MCLEAN, S., NURMATOV, U., LIU, J. L., PAGLIARI, C., CAR, J. & SHEIKH, A. 2012. Telehealthcare for chronic obstructive pulmonary disease: Cochrane Review and metaanalysis. Br J Gen Pract, 62, e739-749.
    • MCLEAN, S., SHEIKH, A., CRESSWELL, K., NURMATOV, U., MUKHERJEE, M., HEMMI, A. & PAGLIARI, C. 2013. The impact of telehealthcare on the quality and safety of care: a systematic overview. PLoS One, 8, e71238.
    • MELTZER, E. O., KELLEY, N. & HOVELL, M. F. 2008. Randomized, cross-over evaluation of mobile phone vs paper diary in subjects with mild to moderate persistent asthma. Open Respir Med J, 2, 72-79.
    • MENEZES, A. M., HALLAL, P. C., PEREZ-PADILLA, R., JARDIM, J. R., MUINO, A., LOPEZ, M. V., VALDIVIA, G., MONTES DE OCA, M., TALAMO, C., PERTUZE, J. & VICTORA, C. G. 2007. Tuberculosis and airflow obstruction: evidence from the PLATINO study in Latin America. Eur Respir J, 30, 1180-1185.
    • MENTEN, P., WUYTS, A. & VAN DAMME, J. 2002. Macrophage inflammatory protein-1. Cytokine Growth Factor Rev, 13, 455-481.
    • MILLARES, L., FERRARI, R., GALLEGO, M., GARCIA-NUNEZ, M., PEREZ-BROCAL, V., ESPASA, M., POMARES, X., MONTON, C., MOYA, A. & MONSO, E. 2014. Bronchial microbiome of severe COPD patients colonised by pseudomonas aeruginosa. Eur Journal Clin Microbiol Infect Dis, 33, 1101-1111.
    • MILLER, C. S., FOLEY, J. D., BAILEY, A. L., CAMPELL, C. L., HUMPHRIES, R. L., CHRISTODOULIDES, N., FLORIANO, P. N., SIMMONS, G., BHAGWANDIN, B., JACOBSON, J. W., REDDING, S. W., EBERSOLE, J. L. & MCDEVITT, J. T. 2010. Current developments in salivary diagnostics. Biomark Med, 4, 171-189.
    • MILLER, C. S., FOLEY, J. D., FLORIANO, P. N., CHRISTODOULIDES, N., EBERSOLE, J. L., CAMPBELL, C. L., BAILEY, A. L., ROSE, B. G., KINANE, D. F., NOVAK, M. J., MCDEVITT, J. T., DING, X. & KRYSCIO, R. J. 2014. Utility of salivary biomarkers for demonstrating acute myocardial infarction. J Dent Res, 93, 72-79.
    • MINOV, J., KARADZINSKA-BISLIMOVSKA, J., VASILEVSKA, K., STOLESKI, S. & MIJAKOSKI, D. 2015. Course of COPD Assessment Test (CAT) scores during bacterial exacerbations of chronic obstructive pulmonary disease treated in outpatient setting. Open Respir Med J, 9, 39-45.
    • MIRAVITLLES, M., ESPINOSA, C., FERNANDEZ-LASO, E., MARTOS, J. A., MALDONADO, J. A. & GALLEGO, M. 1999. Relationship between bacterial flora in sputum and functional impairment in patients with acute exacerbations of COPD. Study group of bacterial infection in COPD. Chest, 116, 40-46.
    • MOHAMED, R., CAMPBELL, J. L., COOPER-WHITE, J., DIMESKI, G. & PUNYADEERA, C. 2012. The impact of saliva collection and processing methods on CRP, IgE, and myoglobin immunoassays. Clin Transl Med, 1, 19.
    • MOLET, S., BELLEGUIC, C., LENA, H., GERMAIN, N., BERTRAND, C. P., SHAPIRO, S. D., PLANQUOIS, J. M., DELAVAL, P. & LAGENTE, V. 2005. Increase in macrophage elastase (MMP-12) in lungs from patients with chronic obstructive pulmonary disease. Inflamm Res, 54, 31-36.
    • MONTUSCHI, P., COLLINS, J. V., CIABATTONI, G., LAZZERI, N., CORRADI, M., KHARITONOV, S. A. & BARNES, P. J. 2000. Exhaled 8-isoprostane as an in vivo biomarker of lung oxidative stress in patients with COPD and healthy smokers. Am J Respir Crit Care Med, 162, 1175-1177.
    • MONTUSCHI, P., KHARITONOV, S. A., CIABATTONI, G. & BARNES, P. J. 2003. Exhaled leukotrienes and prostaglandins in COPD. Thorax, 58, 585-588.
    • MORREN, M., DULMEN, S., OUWERKERK, J. & BENSING, J. 2009. Compliance with momentary pain measurement using electronic diaries: a systematic review. Eur J Pain, 13, 354-365.
    • MOYA, F., NIETO, A. & JL, R. C. 1975. Calcitonin biosynthesis: evidence for a precursor. Eur J Biochem, 55, 407-413.
    • MUKAIDA, N. 2003. Pathophysiological roles of interleukin-8/CXCL8 in pulmonary diseases. Am J Physiol Lung Cell Mol Physiol, 284, L566-577.
    • MÜLLER, B., WHITE, J. C., NYLÉN, E. S., SNIDER, R. H., BECKER, K. L. & HABENER, J. F. 2001. Ubiquitous expression of the calcitonin-I gene in multiple tissues in response to sepsis. J Clin Endocrinol Metab, 86, 396-404.
    • MUTLU, G. M., GAREY, K. W., ROBBINS, R. A., DANZIGER, L. H. & RUBINSTEIN, I. 2001. Collection and analysis of exhaled breath condensate in humans. Am J Respir Crit Care Med, 164, 731-737.
    • NAKAMURA, H. 2011. Genetics of COPD. Allergol Int, 60, 253-258.
    • NAKANO, Y., MURO, S., SAKAI, H., HIRAI, T., CHIN, K., TSUKINO, M., NISHIMURA, K., ITOH, H., PARE, P. D., HOGG, J. C. & MISHIMA, M. 2000. Computed tomographic measurements of airway dimensions and emphysema in smokers - Correlation with lung function. Am J Respir Crit Care Med, 162, 1102-1108.
    • NARHI, T. O., MEURMAN, J. H., AINAMO, A., NEVALAINEN, J. M., SCHMIDTKAUNISAHO, K. G., SIUKOSAARI, P., VALVANNE, J., ERKINJUNTTI, T., TILVIS, R. & MAKILA, E. 1992. Association between salivary flow rate and the use of systemic medication among 76-, 81-, and 86-year-old inhabitants in Helsinki, Finland. J Dent Res, 71, 1875-1880.
    • NATIONAL INSTITUE FOR HEALTH AND CLINICAL EXCELLENCE (NICE). 2010. Chronic obstructive pulmonary disease in over 16s: diagnosis and management (CG101). [Accessed 13th December 2015].
    • NAVAZESH, M. 1993. Methods for collecting saliva. Ann N Y Acad Sci, 694, 72-77.
    • NEDERFORS, T., TWETMAN, S. & DAHLOF, C. 1989. Effects of the thiazide diuretic bendroflumethiazide on salivary flow-rate and composition. Scand J Dent Res, 97, 520- 527.
    • NEDERFORS, T., DAHLOF, C., ERICSSON, T. & TWETMAN, S. 1995. Effects of the antihypertensive drug captopril on human salivary secretion and composition. Eur J Oral Sci, 103, 351-354.
    • NEDERFORS, T., NAUNTOFTE, B. & TWETMAN, S. 2004. Effects of furosemide and bendroflumethiazide on saliva flow rate and composition. Arch Oral Biol, 49, 507-513.
    • NEWMAN, J. D. & TURNER, A. P. 2005. Home blood glucose biosensors: a commercial perspective. Biosensors and Bioelectronics, 20, 2435-2453.
    • NEYRAUD, E., PALICKI, O., SCHWARTZ, C., NICKLAUS, S. & FERON, G. 2012. Variability of human saliva composition: Possible relationships with fat perception and liking. Arch Oral Biol, 57, 556-566.
    • NIEWOEHNER, D. E. 2006. The impact of severe exacerbations on quality of life and the clinical course of chronic obstructive pulmonary disease. Am J Med, 119, 38-45.
    • NIZAM, N., GUMUS, P., PITKANEN, J., TERVAHARTIALA, T., SORSA, T. & BUDUNELI, N. 2014. Serum and salivary matrix metalloproteinases, neutrophil elastase, myeloperoxidase in patients with chronic or aggressive periodontitis. Inflammation, 37, 1771-1778.
    • NUNES, L. A., BRENZIKOFER, R. & MACEDO, D. V. 2011. Reference intervals for saliva analytes collected by a standardized method in a physically active population. Clin Biochem, 44, 1440-1444.
    • NUNES, L. A., MUSSAVIRA, S. & BINDHU, O. S. 2015. Clinical and diagnostic utility of saliva as a non-invasive diagnostic fluid: a systematic review. Biochem Med, 25, 177- 192.
    • NURKKA, A., OBIERO, J., KAYHTY, H. & SCOTT, J. A. 2003. Effects of sample collection and storage methods on antipneumococcal immunoglobulin A in saliva. Clin Diagn Lab Immunol, 10, 357-361.
    • NYLUND, K. L., ASPAROUHOV, T. & MUTHÉN, B. O. 2007. Deciding on the number of classes in latent class analysis and growth mixture modeling: a Monte Carlo simulation study. Struct Equ Modeling, 14, 535-569.
    • OBERHOFFER, M., STONANS, I., RUSSWURM, S., STONANE, E., VOGELSANG, H., JUNKER, U., JÄGER, L. & REINHART, K. 1999. Procalcitonin expression in human peripheral blood mononuclear cells and its modulation by lipopolysaccharides and sepsis-related cytokines in vitro. J Lab Clin Med, 134, 49-55.
    • OGA, T., NISHIMURA, K., TSUKINO, M., SATO, S., HAJIRO, T. & MISHIMA, M. 2005. Exercise capacity deterioration in patients with COPD - longitudinal evaluation over 5 years. Chest, 128, 62-69.
    • OGA, T., NISHIMURA, K., TSUKINO, M., SATO, S., HAJIRO, T. & MISHIMA, M. 2007. Longitudinal deteriorations in patient reported outcomes in patients with COPD. Respir Med, 101, 146-153.
    • OHLMELER, S., VUOLANTO, M., TOLJAMO, T., VUOPALA, K., SALMENKIVI, K., MYLLARNIEMI, M. & KINNULA, V. L. 2008. Proteomics of human lung tissue identifies surfactant protein A as a marker of chronic obstructive pulmonary disease. J Proteome Res, 7, 5125-5132.
    • OUELLET-MORIN, I., DANESE, A., WILLIAMS, B. & ARSENEAULT, L. 2011. Validation of a high-sensitivity assay for C-reactive protein in human saliva. Brain Behav Immun, 25, 640-646.
    • PACE, T. W. W., NEGI, L. T., DODSON-LAVELLE, B., OZAWA-DE SILVA, B., REDDY, S. D., COLE, S. P., DANESE, A., CRAIGHEAD, L. W. & RAISON, C. L. 2013. Engagement with cognitively-based compassion training is associated with reduced salivary C-reactive protein from before to after training in foster care program adolescents. Psychoneuroendocrinology, 38, 294-299.
    • PAEGEL, B. M. & JOYCE, G. F. 2010. Microfluidic compartmentalized directed evolution. Chem Biol, 17, 717-724.
    • PALLOS, D., LEAO, M. V. P., TOGEIRO, F., ALEGRE, L., RICARDO, L. H., PEROZINI, C. & RUIVO, G. F. 2015. Salivary markers in patients with chronic renal failure. Arch Oral Bio, 60, 1784-1788.
    • PAONE, G., CONTI, V., VESTRI, A., LEONE, A., PUGLISI, G., BENASSI, F., BRUNETTI, G., SCHMID, G., CAMMARELLA, I. & TERZANO, C. 2011. Analysis of sputum markers in the evaluation of lung inflammation and functional impairment in symptomatic smokers and COPD patients. Dis Markers, 31, 91-100.
    • PAPAIOANNOU, A. I., LOUKIDES, S., MINAS, M., KONTOGIANNI, K., BAKAKOS, P., GOURGOULIANIS, K. I., ALCHANATIS, M., PAPIRIS, S. & KOSTIKAS, K. 2011. Exhaled breath condensate pH as a biomarker of COPD severity in ex-smokers. Respir Res, 12, 67.
    • PAPI, A., BELLETTATO, C. M., BRACCIONI, F., ROMAGNOLI, M., CASOLARI, P., CARAMORI, G., FABBRI, L. M. & JOHNSTON, S. L. 2006. Infections and airway inflammation in chronic obstructive pulmonary disease severe exacerbations. Am J Respir Crit Care Med, 173, 1114-1121.
    • PARAMESWARAN, G. I., WRONA, C. T., MURPHY, T. F. & SETHI, S. 2009. Moraxella catarrhalis acquisition, airway inflammation and protease-antiprotease balance in chronic obstructive pulmonary disease. BMC Infect Dis, 9, 178.
    • PARKER, S. G. & HAWLEY, M. S. 2013. Telecare for an ageing population? Age Ageing, 42, 424-425.
    • PATEL, I. S., VLAHOS, I., WILKINSON, T. M. A., LLOYD-OWEN, S. J., DONALDSON, G. C., WILKS, M., REZNEK, R. H. & WEDZICHA, J. A. 2004. Bronchiectasis, exacerbation indices, and inflammation in chronic obstructive pulmonary disease. Am J Respir Crit Care Med, 170, 400-407.
    • PATSALOS, P. N. & BERRY, D. J. 2013. Therapeutic drug monitoring of antiepileptic drugs by use of saliva. Ther Drug Monit, 35, 4-29.
    • PAULETTO, N. C., LIEDE, K., NIEMINEN, A., LARJAVA, H. & UITTO, V. J. 2000. Effect of cigarette smoking on oral elastase activity in adult periodontitis patients. J Periodontol, 71, 58-62.
    • PAUWELS, R. A., BUIST, A. S., MA, P., JENKINS, C. R. & HURD, S. S. 2001. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: National Heart, Lung, and Blood Institute and World Health Organisation Global Initiative for Chronic Obstructive Lung Disease (GOLD): executive summary. Respir Care, 46, 798-825.
    • PAUWELS, R., CALVERLEY, P., BUIST, A. S., RENNARD, S., FUKUCHI, Y., STAHL, E. & LOFDAHL, C. G. 2004. COPD exacerbations: the importance of a standard definition. Respir Med, 98, 99-107.
    • PEACOCK, J. L., ANDERSON, H. R., BREMNER, S. A., MARSTON, L., SEEMUNGAL, T. A., STRACHAN, D. P. & WEDZICHA, J. A. 2011. Outdoor air pollution and respiratory health in patients with COPD. Thorax, 66, 591-596.
    • PEDERSON, E. D., STANKE, S. R., WHITENER, S. J., SEBASTIANI, P. T., LAMBERTS, B. L. & TURNER, D. W. 1995. Salivary levels of α2-macroglobulin, α1-antitrypsin, Creactive protein, cathepsin G and elastase in humans with or without destructive. J Periodont, 40, 1151-1155.
    • PERALBO-MOLINA, A., CALDERÓN-SANTIAGO, M., PRIEGO-CAPOTE, F., JURADOGÁMEZ, B. & LUQUE DE CASTRO, M. D. 2015. Development of a method for metabolomic analysis of human exhaled breath condensate by gas chromatographymass spectrometry in high resolution mode. Anal Chim Acta, 887, 118-126.
    • PERERA, W. R., HURST, J. R., WILKINSON, T. M., SAPSFORD, R. J., MULLEROVA, H., DONALDSON, G. C. & WEDZICHA, J. A. 2007. Inflammatory changes, recovery and recurrence at COPD exacerbation. Eur Respir J, 29, 527-534.
    • PERREN, A., CERUTTI, B., LEPORI, M., SENN, V., CAPELLI, B., DUCHINI, F. & DOMENIGHETTI, G. 2008. Influence of steroids on procalcitonin and C-reactive protein in patients with COPD and community-acquired pneumonia. Infection, 36, 163- 166.
    • PETTY, T. L. 2006. The history of COPD. Int J Chron Obstruct Pulmon Dis, 1, 3-14.
    • PFAFFE, T., COOPER-WHITE, J., BEYERLEIN, P., KOSTNER, K. & PUNYADEERA, C. 2011. Diagnostic potential of saliva: current state and future applications. Clin Chem, 57, 675-687.
    • PHILLIPS, C., MAC PARTHALÁIN, N., SYED, Y., DEGANELLO, D., CLAYPOLE, T. & LEWIS, K. 2014. Short-term intra-subject variation in exhaled volatile organic compounds (VOCs) in COPD patients and healthy controls and its effect on disease classification. Metabolites, 4, 300-318.
    • PIERCE, R. A., MOORE, C. H. & ARIKAN, M. C. 2006. Positive transcriptional regulatory element located within exon 1 of elastin gene. Am J Physiol Lung Cell Mol Physiol, 291, L391-399.
    • PINTO, L. M., ALGHAMDI, M., BENEDETTI, A., ZAIHRA, T., LANDRY, T. & BOURBEAU, J. 2015. Derivation and validation of clinical phenotypes for COPD: a systematic review. Respir Res, 16, 50.
    • PINTO-PLATA, V. M., MULLEROVA, H., TOSO, J. F., FEUDJO-TEPIE, M., SORIANO, J. B., VESSEY, R. S. & CELLI, B. R. 2006. C-reactive protein in patients with COPD, control smokers and non-smokers. Thorax, 61, 23-28.
    • POLISENA, J., TRAN, K., CIMON, K., HUTTON, B., MCGILL, S., PALMER, K. & SCOTT, R. E. 2010. Home telehealth for chronic obstructive pulmonary disease: a systematic review and meta-analysis. J Telemed Telecare, 16, 120-127.
    • POSADA, D. & BUCKLEY, T. R. 2004. Model selection and model averaging in phylogenetics: advantages of akaike information criterion and bayesian approaches over likelihood ratio tests. Syst Biol, 53, 793-808.
    • POSLUSZNA, D. & DOBOSZYNSKA, A. 2011. Assessment of nutritional status of patients with chronic obstructive pulmonary disease (COPD) and the impact of diet on COPD risk. Pneumonol Alergol Pol, 79, 109-115.
    • POSTHUMA-TRUMPIE, G. A., KORF, J. & AMERONGEN, A. 2008. Lateral flow (immuno)assay: its strengths, weaknesses, opportunities and threats. A literature survey. Anal Bioanal Chem, 393, 569-582.
    • POSTMA, D. S., BRUSSELLE, G., BUSH, A. & HOLLOWAY, J. W. 2011. I have taken my umbrella, so of course it does not rain. Thorax, 67, 88-89.
    • POWELL, D. J. H., LIOSSI, C., MOSS-MORRIS, R. & SCHLOTZ, W. 2013. Unstimulated cortisol secretory activity in everyday life and its relationship with fatigue and chronic fatigue syndrome: a systematic review and subset meta-analysis. Psychoneuroendocrinology, 38, 2405-2422.
    • PRESCOTT, E., BJERG, A. M., ANDERSEN, P. K., LANGE, P. & VESTBO, J. 1997. Gender difference in smoking effects on lung function and risk of hospitalisation for COPD: results from a Danish longitudinal population study. Eur Respir J, 10, 822-827.
    • PUNEKAR, Y. S., SHUKLA, A. & MÜLLEROVA, H. 2014. COPD management costs according to the frequency of COPD exacerbations in UK primary care. Int J Chron Obstruct Pulmon Dis, 9, 65-73.
    • PUNYADEERA, C., DIMESKI, G., KOSTNER, K., BEYERLEIN, P. & COOPER-WHITE, J. 2011. One-step homogeneous C-reactive protein assay for saliva. J Immunol Methods, 373, 19-25.
    • QASEEM, A., WILT, T. J., WEINBERGER, S. E., HANANIA, N. A., CRINER, G., VAN DER MOLEN, T., MARCINIUK, D. D., DENBERG, T., SCHUNEMANN, H., WEDZICHA, W., MACDONALD, R. & SHEKELLE, P. 2011. Diagnosis and management of stable chronic obstructive pulmonary disease: a clinical practice guideline update from the American College of Physicians, American College of Chest Physicians, American Thoracic Society, and European Respiratory Society. Ann Intern Med, 155, 179-191.
    • QIU, X. B., THOMPSON, J. A., CHEN, Z. Y., LIU, C. C., CHEN, D. F., RAMPRASAD, S., MAUK, M. G., ONGAGNA, S., BARBER, C., ABRAMS, W. R., MALAMUD, D., CORSTJENS, P. & BAU, H. H. 2009. Finger-actuated, self-contained immunoassay cassettes. Biomed Microdevices, 11, 1175-1186.
    • RABE, K. F., HURD, S., ANZUETO, A., BARNES, P. J., BUIST, S. A., CALVERLEY, P., FUKUCHI, Y., JENKINS, C., RODRIGUEZ-ROISIN, R., VAN WEEL, C. & ZIELINSKI, J. 2007. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med, 176, 532-555.
    • RAD, H. M., RABIEI, M., SOBHANI, A., KHANJANI, M. S., TARAMSAR, M. R. & LEILI, E. K. 2014. Free amino acids in stimulated and unstimulated whole saliva: advantages or disadvantages. J Oral Rehabil, 41, 759-767.
    • RAHIM, Z. H. A. & YAACOB, H. B. 1991. Effects of fasting on saliva composition. J Nihon Univ Sch Dent, 33, 205-210.
    • RAMMAERT, B., VERDIER, N., CAVESTRI, B. & NSEIR, S. 2009. Procalcitonin as a prognostic factor in severe acute exacerbation of chronic obstructive pulmonary disease. Respirology, 14, 969-974.
    • RANTONEN, P. J. & MEURMAN, J. H. 1998. Viscosity of whole saliva. Acta Odontol Scand, 56, 210-214.
    • RAO, N. L., SHETTY, S., D'SOUZA, J., PRASAD, R. M., VISHAL, B., SHARIFF, M. H. & RAGHAVENDRA, U. 2011. Saliva C- reactive protein levels in patients with acute urticaria. Biomed Res, 22, 90-92.
    • RAO, N. L., SHETTY, S., UPADHYAYA, K., R. M, P., LOBO, E. C., KEDILAYA, H. P. & PRASAD, G. 2010. Salivary C-Reactive protein in Hashimoto's thyroiditis and subacute thyroiditis. Int J Inflam, 2010, 514659.
    • REED, G. F., LYNN, F. & MEADE, B. D. 2002. Use of coefficient of variation in assessing variability of quantitative assays. Clin Diagn Lab Immunol, 9, 1235-1239.
    • REID, D. D. & ROSE, G. A. 1964. Assessing the comparability of mortality statistics. Br Med J, 2, 1437-1439.
    • RENNARD, S. I., LOCANTORE, N., DELAFONT, B., TAL-SINGER, R., SILVERMAN, E. K., VESTBO, J., MILLER, B. E., BAKKE, P., CELLI, B., CALVERLEY, P. M. A., COXSON, H., CRIM, C., EDWARDS, L. D., LOMAS, D. A., MACNEE, W., WOUTERS, E. F. M., YATES, J. C., COCA, I. & AGUSTÍ, A. 2015. Identification of five chronic obstructive pulmonary disease subgroups with different prognoses in the ECLIPSE cohort using cluster analysis. Ann Am Thorac Soc, 12, 303-312.
    • RIDKER, P. M. 2003a. C-reactive protein: A simple test to help predict risk of heart attack and stroke. Circulation, 108, e81-85.
    • RIDKER, P. M. 2003b. Clinical application of c-reactive protein for cardiovascular disease detection and prevention. Circulation, 107, 363-369.
    • RING, A. E., CHEONG, K. A., WATKINS, C. L., MEDDIS, D., CELLA, D. & HARPER, P. G. 2008. A randomised study of electronic diary versus paper and pencil collection of patient-reported outcomes in patients with non-small cell lung cancer. Patient, 1, 105- 113.
    • RITCHIE, J., LEWIS, J., MCNAUGHTON NICHOLLS, C., & ORMSTON, R. 2014. Qualitative research practice: A guide for social science students & researchers., London, SAGE.
    • RÖCK, F., BARSAN, N. & WEIMAR, U. 2008. Electronic nose: current status and future trends. Chemical Rev, 108, 705-725.
    • RODRIGUEZ-ROISIN, R. 2000. Toward a consensus definition for COPD exacerbations. Chest, 117, S398-401.
    • ROHDE, G., BORG, I., WIETHEGE, A., KAUTH, M., JERZINOWSKI, S., DINH, T. A. D., BAUER, T. T., BUFE, A. & SCHULTZE-WERNINGHAUS, G. 2008. Inflammatory response in acute viral exacerbations of COPD. Infection, 36, 427-433.
    • ROYAL COLLEGE OF PHYSICIANS, BRITISH. THORACIC. SOCIETY. 2014. COPD Who cares organisational audit 2014. [Accessed 10th December 2015].
    • RUIZ-GONZALEZ, A., LACASTA, D., IBARZ, M., MARTINEZ-ALONSO, M., FALGUERA, M. & PORCEL, J. M. 2008. C-reactive protein and other predictors of poor outcome in patients hospitalized with exacerbations of chronic obstructive pulmonary disease. Respirology, 13, 1028-1033.
    • RUTGERS, S. R., POSTMA, D. S., TEN HACKEN, N. H. T., KAUFFMAN, H. F., VAN DER MARK, T. W., KOETER, G. H. & TIMENS, W. 2000a. Ongoing airway inflammation in patients with COPD who do not currently smoke. Thorax, 55, 12-18.
    • RUTGERS, S. R., TIMENS, W., KAUFMANN, H. F., VAN DER MARK, T. W., KOETER, G. H. & POSTMA, D. S. 2000b. Comparison of induced sputum with bronchial wash, bronchoalveolar lavage and bronchial biopsies in COPD. Eur Respir J, 15, 109-115.
    • RYAN, J. M., CORRY, J. R., ATTEWELL, R. & SMITHSON, M. J. 2002. A comparison of an electronic version of the SF-36 General Health Questionnaire to the standard paper version. Qual Life Res, 11, 19-26.
    • RYAN, P. & SAWIN, K. J. 2009. The individual and family self-management theory: background and perspectives on context, process, and outcomes. Nurs Outlook, 57, 217-225.
    • RYBERG, M., MOLLER, C. & ERICSON, T. 1991. Saliva composition and caries development in asthmatic-patients treated with a β2-adrenoceptor agonists - a 4-year follow-up-study. Scand J Dent Res, 99, 212-218.
    • RZEWUSKA, M., MALLEN, C. D., STRAUSS, V. Y., BELCHER, J. & PEAT, G. 2015. Oneyear trajectories of depression and anxiety symptoms in older patients presenting in general practice with musculoskeletal pain: A latent class growth analysis. J Psychosom Res, 79, 195-201.
    • SAHA, S. & BRIGHTLING, C. E. 2006. Eosinophilic airway inflammation in COPD. Int J Chron Obstruct Pulmon Dis, 1, 39-47.
    • SAJID, M., KAWDE, A.-N. & DAUD, M. 2015. Designs, formats and applications of lateral flow assay: a literature review. J Saudi Chem Soc, 19, 689-705.
    • SALAMZADEH, J., DADASHZADEH, S., HABIBI, M. & ESTIFAIE, S. 2008. Serum and saliva theophylline levels in adult outpatients with asthma and chronic obstructive pulmonary disease (COPD): a cross-sectional study. Iran J Pharm Res, 7, 83-87.
    • SAMEER, H. K. (2010). Porosity measurements of cellulose acetate filters for some brands of cigarette using mercury porosimeter. Al-Mustansiriyah Journal of Science مولع ةلجم ةيرصنتسملا, 21(2), 57-66.
    • SAMPSONAS, F., KARKOULIAS, K., KAPARIANOS, A. & SPIROPOULOS, K. 2006. Genetics of chronic obstructive pulmonary disease, beyond α1-antitrypsin deficiency. Curr Med Chem, 13, 2857-2873.
    • SANDELOWSKY, H., STALLBERG, B., NAGER, A. & HASSELSTROM, J. 2011. The prevalence of undiagnosed chronic obstructive pulmonary disease in a primary care population with respiratory tract infections - a case finding study. BMC Fam Pract, 12, 122.
    • SANTO TOMAS, L. H. 2011. Emphysema and chronic obstructive pulmonary disease in coal miners. Curr Opin Pulm Med, 17, 123-125.
    • SANTOS, N. C., JAMELLI, S., COSTA, L., BARACHO, C., MEDEIROS, D., RIZZO, J. A. & SARINHO, E. 2012. Assessing caries, dental plaque and salivary flow in asthmatic adolescents using inhaled corticosteroids. Allergol Immunopathol (Madr), 40, 220-224.
    • SAPEY, E. & STOCKLEY, R. A. 2006. COPD exacerbations. 2: aetiology. Thorax, 61, 250- 258.
    • SCHIPPER, R., LOOF, A., DE GROOT, J., HARTHOORN, L., DRANSFIELD, E. & VAN HEERDE, W. 2007. SELDI-TOF-MS of saliva: methodology and pre-treatment effects. J Chromatogr B Analyt Technol Biomed Life Sci, 847, 45-53.
    • SCHUETZ, P., MULLER, B., CHRIST-CRAIN, M., STOLZ, D., TAMM, M., BOUADMA, L., LUYT, C. E., WOLFF, M., CHASTRE, J., TUBACH, F., KRISTOFFERSEN, K. B., BURKHARDT, O., WELTE, T., SCHROEDER, S., NOBRE, V., WEI, L., BHATNAGAR, N., BUCHER, H. C. & BRIEL, M. 2012. Procalcitonin to initiate or discontinue antibiotics in acute respiratory tract infections. Cochrane Database of Systematic Reviews, 9, CD007498.
    • SCHWARTZ, E. B. & GRANGER, D. A. 2004. Transferrin enzyme immunoassay for quantitative monitoring of blood contamination in saliva. Clin Chem, 50, 654-656.
    • SEDENO, M. F., NAULT, D., HAMD, D. H. & BOURBEAU, J. 2009. A self-management education program including an action plan for acute COPD exacerbations. COPD, 6, 352-358.
    • SEEMUNGAL, T. A. R. & WEDZICHA, J. A. 2014. Exacerbation frequency and FEV1 decline of COPD: is it geographic? Eur Respir J, 43, 1220-1222.
    • SETHI, S., MUSCARELLA, K., EVANS, N., KLINGMAN, K. L., GRANT, B. J. B. & MURPHY, T. F. 2000. Airway inflammation and etiology of acute exacerbations of chronic bronchitis. Chest, 118, 1557-1565.
    • SHAFIEK, H., FIORENTINO, F., MERINO, J. L., LOPEZ, C., OLIVER, A., SEGURA, J., DE PAUL, I., SIBILA, O., AGUST, A. & COSIO, B. G. 2015. Using the electronic nose to identify airway infection during COPD exacerbations. Plos One, 10, 16.
    • SHAHAB, L., JARVIS, M. J., BRITTON, J. & WEST, R. 2006. Prevalence, diagnosis and relation to tobacco dependence of chronic obstructive pulmonary disease in a nationally representative population sample. Thorax, 61, 1043-1047.
    • SHAPIRO, S. D. 2002. Proteinases in chronic obstructive pulmonary disease. Biochem Soc Trans, 30, 98-102.
    • SHAW, J. G., VAUGHAN, A., DENT, A. G., O'HARE, P. E., GOH, F., BOWMAN, R. V., FONG, K. M. & YANG, I. A. 2014. Biomarkers of progression of chronic obstructive pulmonary disease (COPD). J Thorac Dis, 6, 1532-1547.
    • SHI, Y., LIU, C. H., ROBERTS, A. I., DAS, J., XU, G., REN, G., ZHANG, Y., ZHANG, L., YUAN, Z. R., TAN, H. S., DAS, G. & DEVADAS, S. 2006. Granulocyte-macrophage colony-stimulating factor (GM-CSF) and T-cell responses: what we do and don't know. Cell Res, 16, 126-133.
    • SHIRTCLIFF, E. A., GRANGER, D. A., SCHWARTZ, E. & CURRAN, M. J. 2001. Use of salivary biomarkers in biobehavioral research: cotton-based sample collection methods can interfere with salivary immunoassay results. Psychoneuroendocrinology, 26, 165- 173.
    • SHLOMOWITZ, A. & FEHER, M. D. 2014. Anxiety associated with self monitoring of capillary blood glucose. Br J Diabetes Vasc Dis, 14, 60-63.
    • SHOJAEE, M., FEREYDOONI GOLPASHA, M., MALIJI, G., BIJANI, A., AGHAJANPOUR MIR, S. M. & MOUSAVI KANI, S. N. 2013. C - reactive protein levels in patients with periodontal disease and normal subjects. Int J Mol Cell Med, 2, 151-155.
    • SIAFAKAS, N. M., VERMEIRE, P., PRIDE, N. B., PAOLETTI, P., GIBSON, J., HOWARD, P., YERNAULT, J. C., DECRAMER, M., HIGENBOTTAM, T., POSTMA, D. S. & ET AL. 1995. Optimal assessment and management of chronic obstructive pulmonary disease (COPD). The European Respiratory Society Task Force. Eur Respir J, 8, 1398- 1420.
    • SIBILA, O., GARCIA-BELLMUNT, L., GINER, J., MERINO, J. L., SUAREZ-CUARTIN, G., TORREGO, A., SOLANES, I., CASTILLO, D., VALERA, J. L., COSIO, B. G., PLAZA, V. & AGUSTI, A. 2014. Identification of airway bacterial colonisation by an electronic nose in chronic obstructive pulmonary disease. Respir Med, 108, 1608-1614.
    • SIEGEL, I. A., BENARYEH, H., GOZAL, D., COLIN, A. A., SZARGEL, R. & LAUFER, D. 1990. Comparison of unbound and total serum theophylline concentrations with those of stimulated and unstimulated saliva in asthmatic-children. Ther Drug Monit, 12, 460- 464.
    • SIEMENS. 2016. Multistix 10 SG Reagent Strips [Online]. http://www.healthcare.siemens.co.uk/point-of-care/urinalysis/multistix-10-sg-reagentstrips [Accessed 28th January 2016].
    • SILVA, D. R., GAZZANA, M. B. & KNORST, M. M. 2015. C-reactive protein levels in stable COPD patients: a case-control study. Int J Chron Obstruct Pulmon Dis, 10, 1719-1725.
    • SILVA, G. E., SHERRILL, D. L., GUERRA, S. & BARBEE, R. A. 2004. Asthma as a risk factor for COPD in a longitudinal study. Chest, 126, 59-65.
    • SILVERMAN, E. K. 2006. Progress in chronic obstructive pulmonary disease genetics. Proc Am Thorac Soc, 3, 405-408.
    • SIMON, L., GAUVIN, F., AMRE, D. K., SAINT-LOUIS, P. & LACROIX, J. 2004. Serum procalcitonin and C-reactive protein levels as markers of bacterial infection: a systematic review and meta-analysis. Clin Infect Dis, 39, 206-217.
    • SIMONI, P., MAGLIULO, M., MIRASOLI, M., VESTITO, A., FESTI, D., RODA, G., COLECCHIA, A. & RODA, A. 2013. A new point-of-care portable immunosensor for non-invasive assessment of oro-ileal transit time by oral fluid tauroursodeoxycholate measurement after its oral load. J Pharm Biomed Anal, 81-82, 1-7.
    • SINGH, D., EDWARDS, L., TAL-SINGER, R. & RENNARD, S. 2010. Sputum neutrophils as a biomarker in COPD: findings from the ECLIPSE study. Respir Res, 11, 77.
    • SINGH, D., KOLSUM, U., BRIGHTLING, C. E., LOCANTORE, N., AGUSTI, A. & TALSINGER, R. 2014. Eosinophilic inflammation in COPD: prevalence and clinical characteristics. Eur Respir J, 44, 1697-1700.
    • SKOPOULI, F. N., SIOUNA-FATOUROU, H. I., ZICIADIS, C. & MOUTSOPOULOS, H. M. 1989. Evaluation of unstimulated whole saliva flow rate and stimulated parotid flow as confirmatory tests for xerostomia. Clin Exp Rheumatol, 7, 127-129.
    • SONI, N. J., SAMSON, D. J., GALAYDICK, J. L., VATS, V., PITRAK, D. L. & ARONSON, N. 2012. Procalcitonin-guided antibiotic therapy. Rockville (MD): Agency for Healthcare Research and Quality (US): Comparative effectiveness review, 12(13)- EHC124-EF.
    • SORHEIM, I. C., JOHANNESSEN, A., GULSVIK, A., BAKKE, P. S., SILVERMAN, E. K. & DEMEO, D. L. 2010. Gender differences in COPD: are women more susceptible to smoking effects than men? Thorax, 65, 480-485.
    • SORIANO, J. B. & RODRIGUEZ-ROISIN, R. 2011. Chronic obstructive pulmonary disease overview: epidemiology, risk factors, and clinical presentation. Proc Am Thorac Soc, 8, 363-367.
    • SORIANO, J. B., ZIELINSKI, J. & PRICE, D. 2009. Screening for and early detection of chronic obstructive pulmonary disease. Lancet, 374, 721-732.
    • SPENCER, L., RITCHIE, J., ORMSTON, R., O'CONNOR, W. & BERNARD 2014. Qualitative Research practice: A guide for social science students & researchers. 2nd ed. Los Angles, CA: SAGE.
    • SPIROPOULOS, K., TRAKADA, G., NIKOLAOU, E., PRODROMAKIS, E., EFREMIDIS, G., POULI, A. & KONIAVITOU, A. 2003. Endothelin-1 levels in the pathophysiology of chronic obstructive pulmonary disease and bronchial asthma. Respir Med, 97, 983- 989.
    • SRINIVASAN, V., PAMULA, V. K. & FAIR, R. B. 2004. An integrated digital microfluidic lab-on-a-chip for clinical diagnostics on human physiological fluids. Lab Chip, 4, 310- 315.
    • ST JOHN, A. 2010. The evidence to support point-of-care testing. Clin Biochem Rev, 31, 111- 119.
    • ST JOHN, A. & PRICE, C. P. 2014. Existing and emerging technologies for point-of-care testing. Clin Biochem Rev, 35, 155-167.
    • STEINMETZ, J., RASMUSSEN, L. S. & NIELSEN, S. L. 2006. Long-term prognosis for patients with COPD treated in the prehospital setting: Is it influenced by hospital admission? Chest, 130, 676-680.
    • STENTON, C. 2008. The MRC breathlessness scale. Occup Med, 58, 226-227.
    • STEWART, D. W., SHAMDASANI, P.N. & ROOK, D.W. 2007. Focus Groups: Theory and practice Thousand Oaks, California, SAGE.
    • STINSON, J. N., PETROZ, G. C., TAIT, G., FELDMAN, B. M., STREINER, D., MCGRATH, P. J. & STEVENS, B. J. 2006. e-Ouch: usability testing of an electronic chronic pain diary for adolescents with arthritis. Clin J Pain, 22, 295-305.
    • STOCKLEY, R. A., O'BRIEN, C., PYE, A. & HILL, S. L. 2000. Relationship of sputum color to nature and outpatient management of acute exacerbations of COPD. Chest, 117, 1638-1645.
    • STOCKLEY, R. A. 2002. Neutrophils and the pathogenesis of COPD. Chest, 121, 151S-155S.
    • STOLZ, D., CHRIST-CRAIN, M., BINGISSER, R., LEUPPI, J., MIEDINGER, D., MULLER, C., HUBER, P., MULLER, B. & TAMM, M. 2007a. Antibiotic treatment of exacerbations of COPD: a randomized, controlled trial comparing procalcitoninguidance with standard therapy. Chest, 131, 9-19.
    • STOLZ, D., CHRIST-CRAIN, M., MORGENTHALER, N. G., LEUPPI, J., MIEDINGER, D., BINGISSER, R., MULLER, C., STRUCK, J., MULLER, B. & TAMM, M. 2007b. Copeptin, C-reactive protein, and procalcitonin as prognostic biomarkers in acute exacerbation of COPD. Chest, 131, 1058-1067.
    • STONE, A. A., SHIFFMAN, S., SCHWARTZ, J. E., BRODERICK, J. E. & HUFFORD, M. R. 2002. Patient non-compliance with paper diaries. Br Med J, 324, 1193-1194.
    • STONE, A. A., SHIFFMAN, S., SCHWARTZ, J. E., BRODERICK, J. E. & HUFFORD, M. R. 2003. Patient compliance with paper and electronic diaries. Control Clin Trials, 24, 182-199.
    • STONE, P. J., GOTTLIEB, D. J., OCONNOR, G. T., CICCOLELLA, D. E., BREUER, R., BRYANRHADFI, J., SHAW, H. A., FRANZBLAU, C. & SNIDER, G. L. 1995. Elastin and collagen degredation products in urine of smokers with and without chronic obstructive pulmonary disease. Am J Respir Crit Care Med, 151, 952-959.
    • STRAZDINS, L., MEYERKORT, S., BRENT, V., D'SOUZA, R. M., BROOM, D. H. & KYD, J. M. 2005. Impact of saliva collection methods on sIgA and cortisol assays and acceptability to participants. J Immunol Methods, 307, 167-171.
    • SUGIMOTO, M., WONG, D. T., HIRAYAMA, A., SOGA, T. & TOMITA, M. 2010. Capillary electrophoresis mass spectrometry-based saliva metabolomics identified oral, breast and pancreatic cancer-specific profiles. Metabolomics, 6, 78-95.
    • SUND, Z. M., POWELL, T., GREENWOOD, R. & JARAD, N. A. 2009. Remote daily realtime monitoring in patients with COPD - A feasibility study using a novel device. Respir Med, 103, 1320-1328.
    • SWEE, M. H., PARKS, W. C. & PIERCE, R. A. 1995. Developmental regulation of elastin production. Expression of tropoelastin pre-mRNA persists after down-regulation of steady-state mRNA levels. J Biol Chem, 270, 14899-14906.
    • TABBERER, M., BROOKS, J. & WILCOX, T. 2015. A meta-analysis of four randomized clinical trials to confirm the reliability and responsiveness of the Shortness of Breath with Daily Activities (SOBDA) questionnaire in chronic obstructive pulmonary disease. Health and Qual Life Outcomes, 13, 177.
    • TAKAHASHI, H., NUKIWA, T., YOSHIMURA, K., QUICK, C. D., STATES, D. J., HOLMES, M. D., WHANG-PENG, J., KNUTSEN, T. & CRYSTAL, R. G. 1988. Structure of the human neutrophil elastase gene. J Biol Chem, 263, 14739-14747.
    • TANIGUCHI, M., IIZUKA, J., MURATA, Y., ITO, Y., IWAMIYA, M., MORI, H., HIRATA, Y., MUKAI, Y. & MIKUNI-TAKAGAKI, Y. 2013. Multimolecular salivary mucin complex is altered in saliva of cigarette smokers: detection of disulfide bridges by Raman spectroscopy. Biomed Res Int, 2013, 168765.
    • TASHKIN, D. P. 2011. COPD Progression and individual rates of change in FEV1 and the BODE Index. Am J Respir Crit Care Med, 184, 988-990.
    • TAUB, D. D., LLOYD, A. R., CONLON, K., WANG, J. M., ORTALDO, J., HARADA, A., MATSUSHIMA, K., KELVIN, D. & OPPENHEIM, J. 1993. Recombinant human interferon-inducible protein-10 is a chemoattractant for human monocytes and T lymphocytes and promotes T-cell adhesion to endothelial cells. J Exp Med, 177, 1809- 1814.
    • THIEME, T., YOSHIHARA, P., PIACENTINI, S. & BELLER, M. 1992. Clinical evaluation of oral fluid samples for diagosis of viral hepatitis. J Clin Microbiol, 30, 1076-1079.
    • THOMAS, P. S. 2001. Tumour necrosis factor-alpha: the role of this multifunctional cytokine in asthma. Immunol Cell Biol, 79, 132-140.
    • THOMPSON, A. B., DAUGHTON, D., ROBBINS, R. A., GHAFOURI, M. A., OEHLERKING, M. & RENNARD, S. I. 1989. Intraluminal airway inflammation in chronic bronchitis. Characterisation and correlation with clinical parameters. Am Rev Respir Dis, 140, 1527-1537.
    • THOMSEN, M., INGEBRIGTSEN, T. S., MAROTT, J. L., DAHL, M., LANGE, P., VESTBO, J. & NORDESTGAARD, B. G. 2013. Inflammatory biomarkers and exacerbations in chronic obstructive pulmonary disease. JAMA, 309, 2353-2361.
    • THORLEY, A. J. & TETLEY, T. D. 2007. Pulmonary epithelium, cigarette smoke, and chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis, 2, 409-428.
    • TIPLADY, B., GOODMAN, K., CUMMINGS, G., LYLE, D., CARRINGTON, R., BATTERSBY, C. & RALSTON, S. H. 2010. Patient-reported outcomes in rheumatoid arthritis assessing the equivalence of electronic and paper data collection. Patient, 3, 133-143.
    • TISHLER, M., YARON, I., RAZ, A., MEYER, F. A. & YARON, M. 1996. Salivary eicosanoid concentration in patients with Sjogren's syndrome. Ann Rheum Dis, 55, 202-204.
    • TOKMAN, S., SCHUETZ, P. & BENT, S. 2011. Procalcitonin-guided antibiotic therapy for chronic obstructive pulmonary disease exacerbations. Expert Rev Anti Infect Ther, 9, 727-735.
    • TOPKAS, E., KEITH, P., DIMESKI, G., COOPER-WHITE, J. & PUNYADEERA, C. 2012a. Evaluation of saliva collection devices for the analysis of proteins. Clin Chem Acta, 413, 1066-1070.
    • TOY, E. L., GALLAGHER, K. F., STANLEY, E. L., SWENSEN, A. R. & DUH, M. S. 2010. The economic impact of exacerbations of chronic obstructive pulmonary disease and exacerbation definition: a review. COPD, 7, 214-228.
    • TRAPPENBURG, J., JONKMAN, N., JAARSMA, T., VAN OS-MEDENDORP, H., KORT, H., DE WIT, N., HOES, A. & SCHUURMANS, M. 2013. Self-management: one size does not fit all. Patient Educ Couns, 92, 134-137.
    • TRAVES, S. L., CULPITT, S. V., RUSSELL, R. E., BARNES, P. J. & DONNELLY, L. E. 2002. Increased levels of the chemokines GRO-alpha and MCP-1 in sputum samples from patients with COPD. Thorax, 57, 590-595.
    • TRILCK, M., FLITSCH, J., LUDECKE, D. K., JUNG, R. & PETERSENN, S. 2005. Salivary cortisol measurement - a reliable method for the diagnosis of Cushing's syndrome. Exp Clin Endocrinol Diabetes, 113, 225-230.
    • TSILIGIANNI, I. G., VAN DER MOLEN, T., MORAITAKI, D., LOPEZ, I., KOCKS, J. W. H., KARAGIANNIS, K., SIAFAKAS, N. & TZANAKIS, N. 2012. Assessing health status in COPD. A head-to-head comparison between the COPD assessment test (CAT) and the clinical COPD questionnaire (CCQ). BMC Pulm Med, 12, 20.
    • TSIMOGIANNI, A. M., PAPIRIS, S. A., STATHOPOULOS, G. T., MANALI, E. D., ROUSSOS, C. & KOTANIDOU, A. 2009. Predictors of outcome after exacerbation of chronic obstructive pulmonary disease. J Gen Intern Med, 24, 1043-1048.
    • TSOUMAKIDOU, M., DEMEDTS, I. K., BRUSSELLE, G. G. & JEFFERY, P. K. 2008. Dendritic cells in chronic obstructive pulmonary disease: new players in an old game. Am J Respir Crit Care Med, 177, 1180-1186.
    • TSOUMAKIDOU, M., TZANAKIS, N. & SIAFAKAS, N. M. 2003. Induced sputum in the investigation of airway inflammation of COPD. Respir Med, 97, 863-871.
    • TUMKAYA, M., ATIS, S., OZGE, C., DELIALIOGLU, N., POLAT, G. & KANIK, A. 2007. Relationship between airway colonisation, inflammation and exacerbation frequency in COPD. Respir Med, 101, 729-737.
    • TURNER-STOKES, L., TURTON, C., POPE, F. M. & GREEN, M. 1983. Emphysema and cutis laxa. Thorax, 38, 790-792.
    • ULRIK, C. S., LOKKE, A., DAHL, R., DOLLERUP, J., HANSEN, G., CORDING, P. H. & ANDERSEN, K. K. 2011. Early detection of COPD in general practice. Int J Chron Obstruct Pulmon Dis, 6, 123-127.
    • VAN DER WEEGEN, S., VERWEY, R., SPREEUWENBERG, M., TANGE, H., VAN DER WEIJDEN, T. & DE WITTE, L. 2013. The development of a mobile monitoring and feedback tool to stimulate physical activity of people with a chronic disease in primary care: a user-centered design. JMIR Mhealth Uhealth, 1, e8.
    • VAN DIJK, W. D., VAN DEN BEMT, L., VAN DEN HAAK-RONGEN, S., BISCHOFF, E., VAN WEEL, C., VEEN, J. & SCHERMER, T. R. 2011. Multidimensional prognostic indices for use in COPD patient care. A systematic review. Respir Res, 12, 151.
    • VAN REENEN, A., DE JONG, A. M., DEN TOONDER, J. M. & PRINS, M. W. 2014. Integrated lab-on-chip biosensing systems based on magnetic particle actuation - a comprehensive review. Lab Chip, 14, 1966-1986.
    • VEDEL-KROGH, S., NIELSEN, S. F., LANGE, P., VESTBO, J. & NORDESTGAARD, B. G. 2015. Blood eosinophils and exacerbations in COPD: the Copenhagen general population study. Am J Respir Crit Care Med, DOI: 10.1164/rccm.201509-1869OC.
    • VEERMAN, E. C., VAN DEN KEYBUS, P. A., VISSINK, A. & NIEUW AMERONGEN, A. V. 1996. Human glandular salivas: their separate collection and analysis. Eur J Oral Sci, 104, 346-352.
    • VERNOOY, J. H. J., LINDEMAN, J. H. N., JACOBS, J. A., HANEMAAIJER, R. & WOUTERS, E. F. M. 2004. Increased activity of matrix metalloproteinase-8 and matrix metalloproteinase-9 in induced sputum from patients with COPD. Chest, 126, 1802- 1810.
    • VESTBO, J. & HOGG, J. C. 2006. Convergence of the epidemiology and pathology of COPD. Thorax, 61, 86-88.
    • VESTBO, J., EDWARDS, L. D., SCANLON, P. D., YATES, J. C., AGUSTI, A., BAKKE, P., CALVERLEY, P. M., CELLI, B., COXSON, H. O., CRIM, C., LOMAS, D. A., MACNEE, W., MILLER, B. E., SILVERMAN, E. K., TAL-SINGER, R., WOUTERS, E. & RENNARD, S. I. 2011. Changes in forced expiratory volume in 1 second over time in COPD. N Engl J Med, 365, 1184-1192.
    • VESTBO, J., HURD, S. S., AGUSTI, A. G., JONES, P. W., VOGELMEIER, C., ANZUETO, A., BARNES, P. J., FABBRI, L. M., MARTINEZ, F. J., NISHIMURA, M., STOCKLEY, R. A., SIN, D. D. & RODRIGUEZ-ROISIN, R. 2013. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease GOLD executive summary. Am J Respir Crit Care Med, 187, 347-365.
    • VIGNOLA, A. M., BONANNO, A., MIRABELLA, A., RICCOBONO, L., MIRABELLA, F., PROFITA, M., BELLIA, V., BOUSQUET, J. & BONSIGNORE, G. 1998. Increased levels of elastase and alpha1-antitrypsin in sputum of asthmatic patients. Am J Respir Crit Care Med, 157, 505-511.
    • VIGNOLA, A. M., KIPS, J. & BOUSQUET, J. 2000. Tissue remodeling as a feature of persistent asthma. J Allergy Clin Immunol, 105, 1041-1053.
    • VLAHOS, R., WARK, P. A. B., ANDERSON, G. P. & BOZINOVSKI, S. 2012. Glucocorticosteroids differentially regulate MMP-9 and neutrophil elastase in COPD. PLoS One, 7, e33277.
    • VLAHOS, R. & BOZINOVSKI, S. 2014. Role of alveolar macrophages in chronic obstructive pulmonary disease. Front Immunol, 5, 435.
    • WAGLI, P., CHANG, Y. C., HOMSY, A., HVOZDARA, L., HERZIG, H. P. & DE ROOIJ, N. F. 2013. Microfluidic droplet-based liquid-liquid extraction and on-chip IR spectroscopy detection of cocaine in human saliva. Anal Chem, 85, 7558-7565.
    • WALKER, I., SIGOUIN, C., SEK, J., ALMONTE, T., CARRUTHERS, J., CHAN, A., PAI, M. & HEDDLE, N. 2004. Comparing hand-held computers and paper diaries for haemophilia home therapy: a randomized trial. Haemophilia, 10, 698-704.
    • WALSH, N. P., MONTAGUE, J. C., CALLOW, N. & ROWLANDS, A. V. 2004. Saliva flow rate, total protein concentration and osmolality as potential markers of whole body hydration status during progressive acute dehydration in humans. Arch Oral Biol, 49, 149-154.
    • WALT, D. R., BLICHARZ, T. M., HAYMAN, R. B., RISSIN, D. M., BOWDEN, M., SIQUEIRA, W. L., HELMERHORST, E. J., GRAND-PIERRE, N., OPPENHEIM, F. G., BHATIA, J. S., LITTLE, F. F. & BRODY, J. S. 2007. Microsensor arrays for saliva diagnostics. In: MALAMUD, D. & NIEDBALA, R. S. (eds.) Oral-Based Diagnostics. Oxford: Blackwell Publishing, 389-400.
    • WALTERS, E. H., WALTERS, J., WILLS, K. E., ROBINSON, A. & WOOD-BAKER, R. 2012. Clinical diaries in COPD: compliance and utility in predicting acute exacerbations. Int J Chron Obstruct Pulmon Dis, 7, 427-435.
    • WANG, L. L., TANG, Y. F., LIU, S., MAO, S. T., LING, Y., LIU, D., HE, X. Y. & WANG, X. G. 2013. Metabonomic profiling of serum and urine by (1)H NMR-based spectroscopy discriminates patients with chronic obstructive pulmonary disease and healthy individuals. PLoS One, 8, e65675.
    • WANG, S., TASOGLU, S., CHEN, P. Z., CHEN, M., AKBAS, R., WACH, S., OZDEMIR, C. I., GURKAN, U. A., GIGUEL, F. F., KURITZKES, D. R. & DEMIRCI, U. 2014. Micro-a-fluidics ELISA for rapid CD4 cell count at the point-of-care. Sci Rep, 4, 3796.
    • WANG, T. S., MAO, Y. M., SUN, Y. M. & LOU, Y. J. 2012. Pulmonary embolism in patients with chronic obstructive pulmonary disease exacerbations of unknown origin: clinical characteristics and risk factors. Zhonghua Jie He He Hu Xi Za Zhi, 35, 259-263.
    • WARK, P. A., TOOZE, M., POWELL, H. & PARSONS, K. 2013. Viral and bacterial infection in acute asthma and chronic obstructive pulmonary disease increases the risk of readmission. Respirology, 18, 996-1002.
    • WARWICK, G., THOMAS, P. S. & YATES, D. H. 2013. Non-invasive biomarkers in exacerbations of obstructive lung disease. Respirology, 18, 874-884.
    • WASCHKI, B., KIRSTEN, A., HOLZ, O., MULLER, K. C., MEYER, T., WATZ, H. & MAGNUSSEN, H. 2011. Physical activity is the strongest predictor of all-cause mortality in patients with COPD: a prospective cohort study. Chest, 140, 331-342.
    • WASHKO, G. R. 2012. The role and potential of imaging in COPD. Med Clin North Am, 96, 729-743.
    • WEDZICHA, J. A. & DONALDSON, G. C. 2003. Exacerbations of chronic obstructive pulmonary disease. Respir care, 48, 1204-1213.
    • WEDZICHA, J. A. & SEEMUNGAL, T. A. R. 2007. COPD exacerbations: defining their cause and prevention. Lancet, 370, 786-796.
    • WEDZICHA, J. A. & VESTBO, J. 2012. Can patients with COPD self-manage? Lancet, 380, 624-625.
    • WEDZICHA, J. A., BRILL, S. E., ALLINSON, J. P. & DONALDSON, G. C. 2013. Mechanisms and impact of the frequent exacerbator phenotype in chronic obstructive pulmonary disease. BMC Med, 11, 181.
    • WEIGL, B., DOMINGO, G., LABARRE, P. & GERLACH, J. 2008. Towards non- and minimally instrumented, microfluidics-based diagnostic devices. Lab Chip, 8, 1999- 2014.
    • WILKINSON, T. M., DONALDSON, G. C., HURST, J. R., SEEMUNGAL, T. A. & WEDZICHA, J. A. 2004. Early therapy improves outcomes of exacerbations of chronic obstructive pulmonary disease. Am J Respir Crit Care Med, 169, 1298-1303.
    • WILKINSON, T. M., HURST, J. R., PERERA, W. R., WILKS, M., DONALDSON, G. C. & WEDZICHA, J. A. 2006. Effect of interactions between lower airway bacterial and rhinoviral infection in exacerbations of COPD. Chest, 129, 317-324.
    • WILLIAMSON, S., MUNRO, C., PICKLER, R., GRAP, M. J. & ELSWICK, R. K. 2012. Comparison of biomarkers in blood and saliva in healthy adults. Nurs Res Pract, 2012, 246178.
    • WILSON, M. L. & GAIDO, L. 2004. Laboratory diagnosis of urinary tract infections in adult patients. Clin Infect Dis, 38, 1150-1158.
    • WISE, S. G. & WEISS, A. S. 2009. Tropoelastin. Int J Biochem Cell Biol, 41, 494-497.
    • WONG, D. T. 2008. Diagnostics other than blood. Salivary Diagnostics, 94-103.
    • WORTZ, K., CADE, A., MENARD, J. R., LURIE, S., LYKENS, K., BAE, S., JACKSON, B., SU, F. H., SINGH, K. & COULTAS, D. 2012. A qualitative study of patients' goals and expectations for self-management of COPD. Prim Care Respir J, 21, 384-391.
    • WU, S. J., CHEN, P., JIANG, X. N. & LIU, Z. J. 2005. C-reactive protein level and the correlation between lung function and CRP levels in patients with chronic obstructive pulmonary diseases. Zhong Nan Da Xue Xue Bao Yi Xue Ban, 30, 444-446.
    • XIAO, H., ZHANG, L., ZHOU, H., LEE, J. M., GARON, E. B. & WONG, D. T. W. 2012. Proteomic analysis of human saliva from lung cancer patients using two-dimensional difference gel electrophoresis and mass spectrometry. M JAHANGIR NEJAD, M., BOROUJERDI, M. G. & AZADI, K. 2015. Inveol Cell Proteomics, 11.
    • YAN, Y. Z. & ET AL. 1988. Change of neutrophil elastase in COPD and the role of elastase in experimental pulmonary hypertension. Zhonghua Jie He He Hu Xi Za Zhi, 11, 324- 384.
    • YANG, I. A., RELAN, V., WRIGHT, C. M., DAVIDSON, M. R., SRIRAM, K. B., SAVARIMUTHU FRANCIS, S. M., CLARKE, B. E., DUHIG, E. E., BOWMAN, R. V. & FONG, K. M. 2011. Common pathogenic mechanisms and pathways in the development of COPD and lung cancer. Expert Opin Ther Targets, 15, 439-456.
    • YIGLA, M., BERKOVICH, Y. & NAGLER, R. M. 2007. Oxidative stress indices in COPD-- Broncho-alveolar lavage and salivary analysis. Arch Oral Biol, 52, 36-43.
    • YIN, P., ZHANG, M., LI, Y., JIANG, Y. & ZHAO, W. 2011. Prevalence of COPD and its association with socioeconomic status in China: findings from China chronic disease risk factor Ssrveillance 2011. BMC Public Health, 11, 586.
    • YOHANNES, A. M. & ALEXOPOULOS, G. S. 2014. Depression and anxiety in patients with COPD. Eur Respir Rev, 23, 345-349.
    • YOUSEFIMANESH, H., ROBATI, M., MALEKZADEH, H., JAHANGIRNEZHAD, M., BOROUJERDNIA, M. G. & AZADI, K. 2015. Investigation of the association between salivary procalcitonin concentration and chronic periodontitis. Cell J, 17, 559-563.
    • YUDKIN, J. S., STEHOUWER, C., EMEIS, J. & COPPACK, S. 1999. C-reactive protein in healthy subjects: associations with obesity, insulin resistance, and endothelial dysfunction a potential role for cytokines originating from adipose tissue? Arterioscler Thromb, Vasc Biol, 19, 972-978.
    • ZHANG, J., WU, L., FENG, M. X., SEXTON, P., BAI, C. X., QU, J. M., MERRILEES, M. & BLACK, P. N. 2011. Pulmonary fibroblasts from COPD patients show an impaired response of elastin synthesis to TGF-beta1. Respir Physiol Neurobiol, 177, 236-240.
    • ZHANG, L., XIAO, H., ZHOU, H., SANTIAGO, S., LEE, J. M., GARON, E. B., YANG, J. P., BRINKMANN, O., YAN, X. M., AKIN, D., CHIA, D., ELASHOFF, D., PARK, N. H. & WONG, D. T. W. 2012. Development of transcriptomic biomarker signature in human saliva to detect lung cancer. Cellular and Molecular Life Sciences, 69, 3341- 3350.
    • ZHANG, Y., BUNJHOO, H., XIONG, W., XU, Y. & YANG, D. 2012b. Association between C-reactive protein concentration and chronic obstructive pulmonary disease: a systematic review and meta-analysis. J Int Med Res, 40, 1629-1635.
    • ZHANG, W. Y., TANG, Y., DU, D., SMITH, J., TIMCHALK, C., LIU, D. L. & LIN, Y. H. 2013. Direct, analysis of trichloropyridinol in human saliva using an Au nanoparticlesbased immunochromatographic test strip for biomonitoring of exposure to chlorpyrifos. Talanta, 114, 261-267.
    • ZHENG, T., ZHU, Z., WANG, Z. D., HOMER, R. J., MA, B., RIESE, R. J., CHAPMAN, H. A., SHAPIRO, S. D. & ELIAS, J. A. 2000. Inducible targeting of IL-13 to the adult lung causes matrix metalloproteinase-and cathepsin-dependent emphysema. J Clin Invest, 106, 1081-1093.
    • ZUMLA, A., AL-TAWFIQ, J. A., ENNE, V. I., KIDD, M., DROSTEN, C., BREUER, J., MULLER, M. A., HUI, D., MAEURER, M., BATES, M., MWABA, P., ALHAKEEM, R., GRAY, G., GAUTRET, P., AL-RABEEAH, A. A., MEMISH, Z. A. & GANT, V. 2014. Rapid point of care diagnostic tests for viral and bacterial respiratory tract infections; needs, advances, and future prospects. Lancet Infect Dis, 14, 1123- 1135.
    • ZWERINK, M., BRUSSE-KEIZER, M., VAN DER VALK, P. D., ZIELHUIS, G. A., MONNINKHOF, E. M., VAN DER PALEN, J., FRITH, P. A. & EFFING, T. 2014. Self management for patients with chronic obstructive pulmonary disease. Cochrane Database Syst Rev, 3, CD002990.
  • Inferred research data

    The results below are discovered through our pilot algorithms. Let us know how we are doing!

    Title Trust
    65
    65%
  • No similar publications.

Share - Bookmark

Cite this article